Inovio Investors Eligible to Lead Securities Fraud Lawsuit

Rosen Law Firm announces class action lawsuit on behalf of INO shareholders

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

Rosen Law Firm, a global investor rights law firm, has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. The lawsuit alleges that Inovio made false and/or misleading statements about its CELLECTRA device manufacturing and the regulatory prospects for its INO-3107 drug candidate.

Why it matters

The lawsuit claims that when the true details about Inovio's manufacturing and regulatory challenges came to light, investors suffered damages. This case highlights the importance of accurate disclosures by pharmaceutical companies to investors, especially around key product development milestones.

The details

According to the lawsuit, Inovio, which describes itself as a 'biotechnology company focused on the discovery, development, and commercialization of DNA medicines,' allegedly made false and/or misleading statements throughout the Class Period about: (1) manufacturing deficiencies for its CELLECTRA device; (2) the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024; (3) the eligibility of INO-3107 for FDA accelerated approval or priority review; and (4) the overall regulatory and commercial prospects for INO-3107.

  • The Class Period is from October 10, 2023 to December 26, 2025.
  • The deadline for investors to join the class action lawsuit is April 7, 2026.

The players

Inovio Pharmaceuticals, Inc.

A biotechnology company focused on the discovery, development, and commercialization of DNA medicines.

Rosen Law Firm

A global investor rights law firm that has announced the class action lawsuit on behalf of Inovio shareholders.

Got photos? Submit your photos here. ›

What they’re saying

“To join the INO class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.”

— Phillip Kim, Esq. (Rosen Law Firm)

What’s next

The deadline for investors to join the class action lawsuit is April 7, 2026.

The takeaway

This case underscores the importance of pharmaceutical companies providing accurate and transparent information to investors, especially around key product development milestones that can significantly impact a company's stock price and shareholder value.